LONDON (Reuters)-Trial researchers said on Monday that an international trial tested the convalescent plasma of COVID-19 patients with moderate and severe illness. The trial stopped severe COVID-19 requiring intensive care after finding no benefit. -19 Enrollment of patients.
The head of the REMAP-CAP trial made this decision after preliminary analysis of more than 900 intensive care intensive care trial participants showed that the treatment of the product-a rich antibody collected from people who have recovered from a pandemic disease Plasma-did not improve results.
The scientist leading the trial said in a statement: “There is no evidence that the use of restorative plasma is harmful” (and) the trial is continuing to recruit hospitalized COVID-1
“From a biological point of view, patients who do not produce antibodies when resuming plasma therapy and patients with too much virus may benefit more than others. We co-led the trial, the clinicians of Gay and St Thomas Hospital, Critical Care Medicine. Professor Manu Shankar-Hari said that we will conduct further analysis.
He added that the initial analysis did not assess the effect of plasma on hospitalized patients with milder illnesses. He said this is “still a very important issue” and will continue to be explored in the ongoing trials.
The basic hypothesis for using restorative plasma as a potential treatment for COVID-19 patients is that the antibodies contained therein can neutralize the virus, prevent its replication and prevent tissue damage.
However, this preliminary analysis that caused REMAP-CAP to suspend the admission of critically ill patients showed that this method has a very low probability of reducing mortality or reducing the number of days requiring intensive care (2.2%).
“Why restorative plasma does not seem to improve outcomes in severe COVID-19 patients hospitalized in the intensive care unit (ICU). It is not clear. However, this may be because the lung damage is too severe to restore the plasma to change.
REMAP-CAP is an international clinical trial to explore potential treatments for COVID-19. It has recruited 4,100 COVID-19 patients in more than 290 clinical locations in Europe, America, Asia, Africa and Oceania.
Another finding from REMAP-CAP showed that the use of Roche Actemra or Sanofi Kevzara arthritis drugs to treat severe COVID-19 patients last week can significantly improve survival rates and reduce the time patients need intensive care.
The trial is also investigating the potential effects of other existing therapies, including anticoagulant drugs, antiplatelet drugs, antibiotics, statins and vitamin C.
Reporting by Kate Kelland; Editing by Nick Macfie